IL17A and colorectal cancer: Similarly, in colorectal cancer, IL-17A increases resistance to anti-PD-1 therapy by upregulating PD-L1 (programmed death-ligand 1) expression through the P65/nuclear respiratory factor 1/miR-15b-5p axis (Liu et al., 2021).